Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Europe reported sales growth YoY by Quarter
Europe reported sales growth YoY (%) (%)
Johnson & Johnson Europe reported sales growth YoY: -0.6% in Q3 2026, down 11.3 pts from a year earlier.
Latest, Q3 2026
-0.6%
Period ended Sep 30, 2026
Change on a year earlier
-11.3 pts
10.7% in Q3 2025
History
36 quarters
Since Q4 2017
Sources
36
Documents cited below
Where the Q3 2026 figure comes from
“|| Europe | 5,405 | 5,440 | (0.6) | 1.0 | (1.6)”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.2 Supplementary Sales Data.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson Europe reported sales growth YoY (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/geo-europe-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.